BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31576152)

  • 1. CP-CRE/non-CP-CRE Stratification And CRE Resistance Mechanism Determination Help In Better Managing CRE Bacteremia Using Ceftazidime-Avibactam And Aztreonam-Avibactam.
    Zou H; Xiong SJ; Lin QX; Wu ML; Niu SQ; Huang SF
    Infect Drug Resist; 2019; 12():3017-3027. PubMed ID: 31576152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant
    Zou C; Wei J; Shan B; Chen X; Wang D; Niu S
    Infect Drug Resist; 2020; 13():3563-3568. PubMed ID: 33116675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant
    Kim T; Lee SC; Bae M; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Chong YP
    Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33334045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study.
    Wei J; Zou C; Wang D; Huang A; Niu S
    J Glob Antimicrob Resist; 2020 Sep; 22():448-451. PubMed ID: 32387260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant
    Sun S; Chen K; Kong X; Tian W; Niu S
    Infect Drug Resist; 2022; 15():2243-2251. PubMed ID: 35510161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center.
    Zhen S; Lin Q; Chen Z; Shen Y; Chen X; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Jiang E; Han M; Wang J; Feng S
    J Infect Chemother; 2024 Jul; 30(7):608-615. PubMed ID: 38215820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
    Chen Y; Huang HB; Peng JM; Weng L; Du B
    Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
    Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
    BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
    Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
    BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam.
    Yang X; Wang D; Zhou Q; Nie F; Du H; Pang X; Fan Y; Bai T; Xu Y
    BMC Microbiol; 2019 Nov; 19(1):240. PubMed ID: 31675928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Wang W; Huang S; Zou C; Ding Y; Wang H; Pu S; Liao Y; Du H; Wang D; Chen L; Niu S
    Front Cell Infect Microbiol; 2021; 11():755763. PubMed ID: 34778107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant
    Ahmed F; Abraham B; Kamal Saeed N; Mohamed Naser H; Sridharan K
    Crit Care Res Pract; 2024; 2024():3427972. PubMed ID: 38868174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae.
    Lima O; Sousa A; Longueira-Suárez R; Filgueira A; Taboada-Martínez C; Portela-Pino C; Nodar A; Vasallo-Vidal F; Martinez-Lamas L; Pérez-Landeiro A; Rubianes M; Pérez-Rodríguez MT
    Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1173-1182. PubMed ID: 35939239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing
    Cui X; Shan B; Zhang X; Qu F; Jia W; Huang B; Yu H; Tang YW; Chen L; Du H
    Front Microbiol; 2020; 11():1365. PubMed ID: 32655534
    [No Abstract]   [Full Text] [Related]  

  • 18. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
    López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
    Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P
    Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of a Stable and Transferable
    Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
    Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.